Abivax ADR [NASDAQ: ABVX] plunged by -$0.38 during the normal trading session on while it closed the day at $5.67.
Abivax ADR stock has also loss -5.66% of its value over the past 7 days. However, ABVX stock has declined by -24.30% in the 3 months of the year. Over the past six months meanwhile, it has lost -36.36% and lost -22.54% year-on date.
The market cap for ABVX stock reached $359.70 million, with 63.35 million shares outstanding and 55.60 million shares in the current float. Compared to the average trading volume of 206.71K shares, ABVX reached a trading volume of 264215 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Abivax ADR [ABVX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABVX shares is $33.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABVX stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Abivax ADR shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on March 20, 2025. While these analysts kept the previous recommendation, JMP Securities raised their target price to Mkt Outperform. The new note on the price target was released on December 04, 2024, representing the official price target for Abivax ADR stock. Previously, the target price had yet another raise to $48, while Laidlaw analysts kept a Buy rating on ABVX stock.
The Average True Range (ATR) for Abivax ADR is set at 0.45 The Price to Book ratio for the last quarter was 8.55, with the Price to Cash per share for the same quarter was set at 2.35.
ABVX stock trade performance evaluation
Abivax ADR [ABVX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.66. With this latest performance, ABVX shares dropped by -18.18% in over the last four-week period, additionally sinking by -36.36% over the last 6 months – not to mention a drop of -60.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABVX stock in for the last two-week period is set at 37.29, with the RSI for the last a single of trading hit 32.35, and the three-weeks RSI is set at 40.55 for Abivax ADR [ABVX]. The present Moving Average for the last 50 days of trading for this stock 6.39, while it was recorded at 5.84 for the last single week of trading, and 8.37 for the last 200 days.
Abivax ADR [ABVX]: An insightful look at the core fundamentals
Abivax ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.82 and a Current Ratio set at 1.82.
Earnings per share (EPS) analysis for Abivax ADR [ABVX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABVX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abivax ADR go to 7.29%.
Abivax ADR [ABVX]: Institutional Ownership
There are presently around $50.21%, or 50.21%% of ABVX stock, in the hands of institutional investors. The top three institutional holders of ABVX stocks are: TCG CROSSOVER MANAGEMENT, LLC with ownership of 6.06 million shares, which is approximately 14.0635%. DEEP TRACK CAPITAL, LP, holding 4.18 million shares of the stock with an approximate value of $$55.26 million in ABVX stocks shares; and DEEP TRACK CAPITAL, LP, currently with $$32.68 million in ABVX stock with ownership which is approximately 5.7405%.
